Plus Historical Income Statement

PSTV Stock

USD 1.20 0.01 0.84%

Historical analysis of Plus Therapeutics income statement accounts such as Research Development of 11.7 M, Total Operating Expenses of 9.3 M, Income Tax Expense of 1.2 M or Total Revenue of 5.6 M can show how well Plus Therapeutics performed in making a profits. Evaluating Plus Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Plus Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Plus Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Plus Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.

About Plus Income Statement Analysis

Plus Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Plus Therapeutics shareholders. The income statement also shows Plus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Plus Therapeutics Income Statement Chart

At this time, Plus Therapeutics' Net Interest Income is fairly stable compared to the past year. Reconciled Depreciation is likely to climb to about 806.7 K in 2025, whereas Selling And Marketing Expenses is likely to drop slightly above 637 K in 2025.

Selling General Administrative Selling And Marketing Expenses Other Operating Expenses Research Development Preferred Stock And Other Adjustments Net Interest Income

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Plus Therapeutics. It is also known as Plus Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Net Interest Income

The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.

Most accounts from Plus Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Plus Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.At this time, Plus Therapeutics' Net Interest Income is fairly stable compared to the past year. Reconciled Depreciation is likely to climb to about 806.7 K in 2025, whereas Selling And Marketing Expenses is likely to drop slightly above 637 K in 2025.

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	712K	628K	565.2K	968.9K
Cost Of Revenue	712K	9.7M	11.1M	11.7M

Depreciation And Amortization Cost Of Revenue

Plus Therapeutics income statement Correlations

	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Net Income	Income Tax Expense	Total Revenue	Gross Profit	Cost Of Revenue	Depreciation And Amortization	Income Before Tax	Total Other Income Expense Net	Net Income From Continuing Ops	Non Operating Income Net Other	Interest Income	Net Interest Income	Reconciled Depreciation
Interest Expense		0.67	0.71	0.77	-0.74	-0.76	0.67	-0.75	0.89	-0.83	0.43	0.76	0.85	-0.3	0.4	-0.06	0.47	-0.55	0.0	0.59	-0.77	0.7
Selling General Administrative	0.67		0.79	0.93	-0.93	-0.91	0.73	-0.91	0.84	-0.88	0.05	0.64	0.46	0.19	0.11	-0.13	0.35	-0.58	0.19	0.5	-0.21	0.29
Selling And Marketing Expenses	0.71	0.79		0.85	-0.85	-0.88	0.51	-0.88	0.88	-0.84	0.07	0.72	0.7	-0.11	0.21	-0.57	0.4	-0.65	0.52	0.68	-0.6	0.62
Other Operating Expenses	0.77	0.93	0.85		-0.92	-0.93	0.87	-0.93	0.93	-0.88	0.13	0.83	0.67	0.11	0.3	-0.19	0.47	-0.65	0.16	0.58	-0.43	0.54
Operating Income	-0.74	-0.93	-0.85	-0.92		0.97	-0.72	0.96	-0.92	0.95	-0.01	-0.62	-0.61	0.1	-0.24	0.2	-0.31	0.75	-0.18	-0.51	0.4	-0.48
Ebit	-0.76	-0.91	-0.88	-0.93	0.97		-0.74	1.0	-0.94	0.95	0.04	-0.66	-0.65	0.1	-0.21	0.34	-0.36	0.74	-0.17	-0.59	0.45	-0.53
Research Development	0.67	0.73	0.51	0.87	-0.72	-0.74		-0.73	0.77	-0.68	0.18	0.78	0.6	0.17	0.38	0.14	0.48	-0.5	-0.21	0.36	-0.3	0.47
Ebitda	-0.75	-0.91	-0.88	-0.93	0.96	1.0	-0.73		-0.93	0.94	0.06	-0.65	-0.63	0.09	-0.16	0.35	-0.35	0.75	-0.18	-0.61	0.44	-0.51
Total Operating Expenses	0.89	0.84	0.88	0.93	-0.92	-0.94	0.77	-0.93		-0.92	0.23	0.79	0.84	-0.23	0.35	-0.22	0.5	-0.68	0.2	0.62	-0.65	0.65
Net Income	-0.83	-0.88	-0.84	-0.88	0.95	0.95	-0.68	0.94	-0.92		-0.1	-0.66	-0.67	0.15	-0.25	0.21	-0.19	0.69	-0.08	-0.49	0.48	-0.51
Income Tax Expense	0.43	0.05	0.07	0.13	-0.01	0.04	0.18	0.06	0.23	-0.1		0.41	0.4	-0.08	0.3	0.33	0.42	0.08	0.04	0.18	-0.42	0.24
Total Revenue	0.76	0.64	0.72	0.83	-0.62	-0.66	0.78	-0.65	0.79	-0.66	0.41		0.8	0.14	0.37	-0.11	0.48	-0.43	0.2	0.56	-0.6	0.66
Gross Profit	0.85	0.46	0.7	0.67	-0.61	-0.65	0.6	-0.63	0.84	-0.67	0.4	0.8		-0.48	0.46	-0.16	0.47	-0.55	0.24	0.6	-0.89	0.83
Cost Of Revenue	-0.3	0.19	-0.11	0.11	0.1	0.1	0.17	0.09	-0.23	0.15	-0.08	0.14	-0.48		-0.2	0.1	-0.08	0.25	-0.1	-0.16	0.6	-0.39
Depreciation And Amortization	0.4	0.11	0.21	0.3	-0.24	-0.21	0.38	-0.16	0.35	-0.25	0.3	0.37	0.46	-0.2		0.15	0.35	-0.11	-0.15	-0.06	-0.36	0.56
Income Before Tax	-0.06	-0.13	-0.57	-0.19	0.2	0.34	0.14	0.35	-0.22	0.21	0.33	-0.11	-0.16	0.1	0.15		-0.11	0.29	-0.55	-0.43	0.31	-0.3
Total Other Income Expense Net	0.47	0.35	0.4	0.47	-0.31	-0.36	0.48	-0.35	0.5	-0.19	0.42	0.48	0.47	-0.08	0.35	-0.11		-0.14	0.26	0.49	-0.4	0.39
Net Income From Continuing Ops	-0.55	-0.58	-0.65	-0.65	0.75	0.74	-0.5	0.75	-0.68	0.69	0.08	-0.43	-0.55	0.25	-0.11	0.29	-0.14		-0.24	-0.72	0.55	-0.69
Non Operating Income Net Other	0.0	0.19	0.52	0.16	-0.18	-0.17	-0.21	-0.18	0.2	-0.08	0.04	0.2	0.24	-0.1	-0.15	-0.55	0.26	-0.24		0.56	-0.29	0.23
Interest Income	0.59	0.5	0.68	0.58	-0.51	-0.59	0.36	-0.61	0.62	-0.49	0.18	0.56	0.6	-0.16	-0.06	-0.43	0.49	-0.72	0.56		-0.66	0.66
Net Interest Income	-0.77	-0.21	-0.6	-0.43	0.4	0.45	-0.3	0.44	-0.65	0.48	-0.42	-0.6	-0.89	0.6	-0.36	0.31	-0.4	0.55	-0.29	-0.66		-0.89
Reconciled Depreciation	0.7	0.29	0.62	0.54	-0.48	-0.53	0.47	-0.51	0.65	-0.51	0.24	0.66	0.83	-0.39	0.56	-0.3	0.39	-0.69	0.23	0.66	-0.89

Click cells to compare fundamentals

Plus Therapeutics Account Relationship Matchups

Plus Therapeutics income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Interest Expense	1.1M	932K	711K	395K	355.5K	337.7K
Selling General Administrative	6.4M	6.9M	10.2M	8.5M	9.8M	10.2M
Selling And Marketing Expenses	643K	468K	0.41	745K	670.5K	637.0K
Other Operating Expenses	9.9M	12.4M	19.9M	18.2M	21.0M	27.8M
Operating Income	(9.6M)	(12.5M)	(19.7M)	(13.3M)	(12.0M)	(12.6M)
Ebit	(7.1M)	(12.9M)	(19.6M)	(13.3M)	(12.0M)	(12.6M)
Research Development	3.5M	5.6M	9.7M	9.7M	11.1M	11.7M
Ebitda	(6.8M)	(12.5M)	(18.9M)	(12.7M)	(11.4M)	(12.0M)
Total Operating Expenses	9.9M	12.4M	19.9M	8.5M	9.8M	9.3M
Net Income	(9.3M)	(14.3M)	(20.8M)	(13.3M)	(12.0M)	(12.6M)
Income Tax Expense	9.5M	1.1M	932K	563K	647.5K	1.2M
Total Revenue	303K	0.0	224K	4.9M	4.4M	5.6M
Gross Profit	(2.4M)	(66K)	(488K)	(4.8M)	(4.3M)	(4.1M)
Cost Of Revenue	2.7M	66K	712K	9.7M	11.1M	11.7M
Depreciation And Amortization	369K	419K	712K	628K	565.2K	968.9K
Income Before Tax	(8.2M)	(13.4M)	(20.3M)	(13.3M)	(15.3M)	(16.1M)
Total Other Income Expense Net	1.3M	(907K)	(563K)	5K	4.5K	4.3K
Net Income From Continuing Ops	(8.2M)	(13.4M)	(20.3M)	(13.3M)	(15.3M)	(16.1M)
Net Income Applicable To Common Shares	(11.4M)	(8.2M)	(13.4M)	(20.3M)	(23.3M)	(24.5M)
Net Interest Income	(1.1M)	(913K)	(564K)	5K	5.8K	6.0K
Reconciled Depreciation	366K	395K	619K	628K	565.2K	806.7K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Plus Stock Analysis

When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Plus Historical Income Statement

About Plus Income Statement Analysis

Plus Therapeutics Income Statement Chart

Other Operating Expenses

Net Interest Income

Plus Therapeutics income statement Correlations

Plus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Plus Therapeutics income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Plus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Ebit	+ 0.97	Operating Income
Ebitda	+ 0.96	Operating Income
Net Income	+ 0.95	Operating Income
Net Income	+ 0.95	Ebit
Net Income	+ 0.94	Ebitda

Total Operating Expenses	- 0.94	Ebit
Total Operating Expenses	- 0.93	Ebitda
Ebitda	- 0.93	Other Operating Expenses
Ebit	- 0.93	Other Operating Expenses
Operating Income	- 0.93	Selling General Administrative
Net Income	- 0.92	Total Operating Expenses